Ads
related to: camp4 therapeutics corp ipo schedule printableworkiva.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
This page was last edited on 5 February 2024, at 11:03 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Some 108 companies conducted their IPO in 2023 and raised $19.4 billion, according to Renaissance Capital. Those figures rose markedly from the 2022 doldrums of 71 IPOs and just $7.7 billion raised.
The company held its IPO in February 2004. [ 2 ] [ 3 ] In 2006 GTx signed a partnership with Ipsen to develop toremifene, a selective estrogen receptor modulator to prevent prostate cancer and to prevent bone loss in men with prostate cancer; the FDA rejected the application to market the drug for this use in 2009, and Ipsen terminated the ...
The U.S. IPO market is staging a strong comeback after two dismal years, thanks to a rally in the stock market and growing optimism of a possible interest rate cut this year. Rapport, backed by ...
Maxim Power Corp. MXG: MBN Corporation MBN: MCAN Mortgage Corporation MKP: McCoy Global Inc. MCB: McEwen Mining Inc. MUX: Mediagrif Interactive Technologies Inc. MDF: Medical Facilities Corporation DR: Medicenna Therapeutics Corp. MDNA: MedReleaf Corp. LEAF: MEG Energy Corp. MEG: Mega Uranium Ltd. MGA: Melcor Developments Ltd. MRD: Melcor Real ...
RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. [ 9 ] [ 10 ] RXi was founded in part by Nobel Prize winner Craig Mello . [ 9 ] In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of ...
Targanta Therapeutics Corporation was a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company also had operations in Indianapolis , Montreal and Toronto . Targanta completed its initial public offering on October 9, 2007 [ 1 ] and traded on the Nasdaq market under the symbol: TARG.